Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.

Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Egyhazi Brage S, Altun M, Uhlen M, Maddalo G.

Mol Syst Biol. 2018 Mar 5;14(3):e7858. doi: 10.15252/msb.20177858.

2.

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, Blank CU, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI.

Nat Med. 2018 Feb;24(2):203-212. doi: 10.1038/nm.4472. Epub 2018 Jan 15.

PMID:
29334371
3.

Immortalization capacity of HPV types is inversely related to chromosomal instability.

Schütze DM, Krijgsman O, Snijders PJ, Ylstra B, Weischenfeldt J, Mardin BR, Stütz AM, Korbel JO, de Winter JP, Meijer CJ, Quint WG, Bosch L, Wilting SM, Steenbergen RD.

Oncotarget. 2016 Jun 21;7(25):37608-37621. doi: 10.18632/oncotarget.8058.

4.

Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.

van den Broek E, Krijgsman O, Sie D, Tijssen M, Mongera S, van de Wiel MA, Belt EJ, den Uil SH, Bril H, Stockmann HB, Ylstra B, Carvalho B, Meijer GA, Fijneman RJ.

Oncotarget. 2016 Nov 8;7(45):73876-73887. doi: 10.18632/oncotarget.12510.

5.

Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients.

Semenova EA, Kwon MC, Monkhorst K, Song JY, Bhaskaran R, Krijgsman O, Kuilman T, Peters D, Buikhuisen WA, Smit EF, Pritchard C, Cozijnsen M, van der Vliet J, Zevenhoven J, Lambooij JP, Proost N, van Montfort E, Velds A, Huijbers IJ, Berns A.

Cell Rep. 2016 Jul 19;16(3):631-43. doi: 10.1016/j.celrep.2016.06.020. Epub 2016 Jun 30.

6.

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

Kemper K, Krijgsman O, Kong X, Cornelissen-Steijger P, Shahrabi A, Weeber F, van der Velden DL, Bleijerveld OB, Kuilman T, Kluin RJC, Sun C, Voest EE, Ju YS, Schumacher TNM, Altelaar AFM, McDermott U, Adams DJ, Blank CU, Haanen JB, Peeper DS.

Cell Rep. 2016 Jun 28;16(1):263-277. doi: 10.1016/j.celrep.2016.05.064. Epub 2016 Jun 16.

7.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

Severson TM, Nevedomskaya E, Peeters J, Kuilman T, Krijgsman O, van Rossum A, Droog M, Kim Y, Koornstra R, Beumer I, Glas AM, Peeper D, Wesseling J, Simon IM, Wessels L, Linn SC, Zwart W.

Oncotarget. 2016 Jun 7;7(23):33901-18. doi: 10.18632/oncotarget.8983.

8.

MITF: More Interesting Traits, Folks!

Kemper K, Krijgsman O, Peeper DS.

Pigment Cell Melanoma Res. 2016 May;29(3):263-5. doi: 10.1111/pcmr.12476. Epub 2016 Mar 31. No abstract available.

PMID:
26999069
9.

miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110.

Bijnsdorp IV, Hodzic J, Lagerweij T, Westerman B, Krijgsman O, Broeke J, Verweij F, Nilsson RJ, Rozendaal L, van Beusechem VW, van Moorselaar JA, Wurdinger T, Geldof AA.

Oncotarget. 2016 Mar 29;7(13):16676-87. doi: 10.18632/oncotarget.7572.

10.

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.

Weeber F, van de Wetering M, Hoogstraat M, Dijkstra KK, Krijgsman O, Kuilman T, Gadellaa-van Hooijdonk CG, van der Velden DL, Peeper DS, Cuppen EP, Vries RG, Clevers H, Voest EE.

Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13308-11. doi: 10.1073/pnas.1516689112. Epub 2015 Oct 12.

11.

High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.

van den Broek E, Dijkstra MJ, Krijgsman O, Sie D, Haan JC, Traets JJ, van de Wiel MA, Nagtegaal ID, Punt CJ, Carvalho B, Ylstra B, Abeln S, Meijer GA, Fijneman RJ.

PLoS One. 2015 Sep 16;10(9):e0138141. doi: 10.1371/journal.pone.0138141. eCollection 2015.

12.

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, Song JY, Kuilman T, Vis DJ, Wessels LF, Voest EE, Schumacher TN, Blank CU, Adams DJ, Haanen JB, Peeper DS.

EMBO Mol Med. 2015 Sep;7(9):1104-18. doi: 10.15252/emmm.201404914.

13.

CopywriteR: DNA copy number detection from off-target sequence data.

Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M, Nevedomskaya E, Xu G, de Ruiter J, Lolkema MP, Ylstra B, Jonkers J, Rottenberg S, Wessels LF, Adams DJ, Peeper DS, Krijgsman O.

Genome Biol. 2015 Feb 27;16:49. doi: 10.1186/s13059-015-0617-1.

14.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Schouten PC, Grigoriadis A, Kuilman T, Mirza H, Watkins JA, Cooke SA, van Dyk E, Severson TM, Rueda OM, Hoogstraat M, Verhagen CV, Natrajan R, Chin SF, Lips EH, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Krijgsman O, Vens C, Peeper D, Nederlof PM, Caldas C, Tutt AN, Wessels LF, Linn SC.

Mol Oncol. 2015 Aug;9(7):1274-86. doi: 10.1016/j.molonc.2015.03.002. Epub 2015 Mar 20.

15.

Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival.

Kwakman R, de Cuba EM, de Winter JP, de Hingh IH, Delis-van Diemen PM, Tijssen M, Rooimans MA, Krijgsman O, Carvalho B, Peters GJ, Bonjer HJ, Meijer GA, Te Velde EA.

Br J Cancer. 2015 Mar 3;112(5):851-6. doi: 10.1038/bjc.2015.18. Epub 2015 Feb 10.

16.

Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma.

Both J, Krijgsman O, Bras J, Schaap GR, Baas F, Ylstra B, Hulsebos TJ.

PLoS One. 2014 Dec 31;9(12):e115835. doi: 10.1371/journal.pone.0115835. eCollection 2014.

17.

Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.

Hoogstraat M, Gadellaa-van Hooijdonk CG, Ubink I, Besselink NJ, Pieterse M, Veldhuis W, van Stralen M, Meijer EF, Willems SM, Hadders MA, Kuilman T, Krijgsman O, Peeper DS, Koudijs MJ, Cuppen E, Voest EE, Lolkema MP.

Pigment Cell Melanoma Res. 2015 May;28(3):318-23. doi: 10.1111/pcmr.12347. Epub 2015 Jan 7.

PMID:
25515853
18.

FocalCall: An R Package for the Annotation of Focal Copy Number Aberrations.

Krijgsman O, Benner C, Meijer GA, van de Wiel MA, Ylstra B.

Cancer Inform. 2014 Dec 1;13:153-6. doi: 10.4137/CIN.S19519. eCollection 2014.

19.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.

Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.

20.

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

Possik PA, Müller J, Gerlach C, Kenski JC, Huang X, Shahrabi A, Krijgsman O, Song JY, Smit MA, Gerritsen B, Lieftink C, Kemper K, Michaut M, Beijersbergen RL, Wessels L, Schumacher TN, Peeper DS.

Cell Rep. 2014 Nov 20;9(4):1375-86. doi: 10.1016/j.celrep.2014.10.024. Epub 2014 Nov 6.

21.

Focal chromosomal copy number aberrations in cancer-Needles in a genome haystack.

Krijgsman O, Carvalho B, Meijer GA, Steenbergen RD, Ylstra B.

Biochim Biophys Acta. 2014 Nov;1843(11):2698-2704. doi: 10.1016/j.bbamcr.2014.08.001. Epub 2014 Aug 7. Review.

22.

Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression.

de Groen FL, Krijgsman O, Tijssen M, Vriend LE, Ylstra B, Hooijberg E, Meijer GA, Steenbergen RD, Carvalho B.

Genes Chromosomes Cancer. 2014 Apr;53(4):339-48. doi: 10.1002/gcc.22144. Epub 2014 Jan 29.

PMID:
24478024
23.

Dissecting the gray zone between follicular lymphoma and marginal zone lymphoma using morphological and genetic features.

Krijgsman O, Gonzalez P, Ponz OB, Roemer MG, Slot S, Broeks A, Braaf L, Kerkhoven RM, Bot F, van Groningen K, Beijert M, Ylstra B, de Jong D.

Haematologica. 2013 Dec;98(12):1921-9. doi: 10.3324/haematol.2013.085118. Epub 2013 Jul 12.

24.

High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis.

van Boerdonk RA, Daniels JM, Bloemena E, Krijgsman O, Steenbergen RD, Brakenhoff RH, Grünberg K, Ylstra B, Meijer CJ, Smit EF, Snijders PJ, Heideman DA.

J Thorac Oncol. 2013 Jun;8(6):711-8. doi: 10.1097/JTO.0b013e3182897c14.

25.

Detection limits of DNA copy number alterations in heterogeneous cell populations.

Krijgsman O, Israeli D, van Essen HF, Eijk PP, Berens ML, Mellink CH, Nieuwint AW, Weiss MM, Steenbergen RD, Meijer GA, Ylstra B.

Cell Oncol (Dordr). 2013 Feb;36(1):27-36. doi: 10.1007/s13402-012-0108-2. Epub 2012 Nov 2.

PMID:
23117839
26.

Focal aberrations indicate EYA2 and hsa-miR-375 as oncogene and tumor suppressor in cervical carcinogenesis.

Bierkens M, Krijgsman O, Wilting SM, Bosch L, Jaspers A, Meijer GA, Meijer CJ, Snijders PJ, Ylstra B, Steenbergen RD.

Genes Chromosomes Cancer. 2013 Jan;52(1):56-68. doi: 10.1002/gcc.22006. Epub 2012 Sep 14.

PMID:
22987659
27.

Genomic aberrations relate early and advanced stage ovarian cancer.

Zaal A, Peyrot WJ, Berns PM, van der Burg ME, Veerbeek JH, Trimbos JB, Cadron I, van Diest PJ, van Wieringen WN, Krijgsman O, Meijer GA, Piek JM, Timmers PJ, Vergote I, Verheijen RH, Ylstra B, Zweemer RP; EORTC GCG Translational Research Group.

Cell Oncol (Dordr). 2012 Jun;35(3):181-8. doi: 10.1007/s13402-012-0077-5. Epub 2012 May 12.

28.

Matching of array CGH and gene expression microarray features for the purpose of integrative genomic analyses.

van Wieringen WN, Unger K, Leday GG, Krijgsman O, de Menezes RX, Ylstra B, van de Wiel MA.

BMC Bioinformatics. 2012 May 4;13:80. doi: 10.1186/1471-2105-13-80.

29.

CGH arrays compared for DNA isolated from formalin-fixed, paraffin-embedded material.

Krijgsman O, Israeli D, Haan JC, van Essen HF, Smeets SJ, Eijk PP, Steenbergen RD, Kok K, Tejpar S, Meijer GA, Ylstra B.

Genes Chromosomes Cancer. 2012 Apr;51(4):344-52. doi: 10.1002/gcc.21920. Epub 2011 Dec 8.

PMID:
22162309
30.

High lymph node yield is related to microsatellite instability in colon cancer.

Belt EJ, te Velde EA, Krijgsman O, Brosens RP, Tijssen M, van Essen HF, Stockmann HB, Bril H, Carvalho B, Ylstra B, Bonjer HJ, Meijer GA.

Ann Surg Oncol. 2012 Apr;19(4):1222-30. doi: 10.1245/s10434-011-2091-7. Epub 2011 Oct 12.

31.

A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response.

Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, Bender RA, Bernards R, Glas AM.

Breast Cancer Res Treat. 2012 May;133(1):37-47. doi: 10.1007/s10549-011-1683-z. Epub 2011 Aug 4.

PMID:
21814749
32.

TSPYL5 suppresses p53 levels and function by physical interaction with USP7.

Epping MT, Meijer LA, Krijgsman O, Bos JL, Pandolfi PP, Bernards R.

Nat Cell Biol. 2011 Jan;13(1):102-8. doi: 10.1038/ncb2142. Epub 2010 Dec 19.

PMID:
21170034
33.

Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.

Gevensleben H, Göhring UJ, Büttner R, Heukamp LC, Kunz G, Dimpfl T, Jackisch C, Ortmann O, Albert US, Bender R, De Snoo F, Krijgsman O, Glas AM, Ergönenc YH, Vogel C, Dykgers A, Langwieder C, Rees M, Anzeneder T.

Int J Mol Med. 2010 Dec;26(6):837-43.

PMID:
21042777
34.

Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.

Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, Bender R, Linn SC, Glas AM, van de Vijver MJ.

Clin Cancer Res. 2009 Nov 15;15(22):7003-11. doi: 10.1158/1078-0432.CCR-09-0449. Epub 2009 Nov 3.

35.

PRAME expression and clinical outcome of breast cancer.

Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R.

Br J Cancer. 2008 Aug 5;99(3):398-403. doi: 10.1038/sj.bjc.6604494. Epub 2008 Jul 22.

Supplemental Content

Loading ...
Support Center